IQVIA HOLDINGS INC

IQVIA’s 2026 H1 biosimilar surge lifts net sales 5.6% and EBITDA over 20%, driven by North America, digital‑health bundling, and supply‑chain resilience.

IQVIA’s July 2026 insider filings reveal routine, rule‑compliant equity purchases and a large director‑officer acquisition—showing strong liquidity management and regulatory transparency.

Brazil’s ANVISA approves Sandoz’s Owozy® semaglutide— a pre‑filled, affordable diabetes drug poised to expand global access and boost Sandoz’s Brazilian portfolio.

New data shows Novo Nordisk’s oral Wegovy gaining market share, boosting margins and positioning the company to outpace Lilly in the U.S. weight‑loss drug race.

IQVIA strengthens board governance by adding former CFO Michael McDonnell, boosting capital allocation, investor relations and compliance for data‑driven healthcare solutions.

Sun Pharma’s June 2026 investor presentation reveals how its diversified specialty generics portfolio, strong R&D pipeline, and ESG focus drive steady global growth and resilient profitability.

IQVIA‑Shilpa‑Orion partnership launches a high‑quality EU‑GMP nivolumab biosimilar, targeting early market entry, cost‑effective pricing, and strong oncology growth.

IQVIA Holdings Inc. is a key analytics partner, offering precise market‑size estimates, reimbursement modeling, and operational insights that drive better pricing, resource allocation, and value‑based care in pharma and healthcare.

IQVIA’s 2026 investor update reveals strategic consolidation of biopharma units, a 120‑country biosimilar expansion, debt reduction, and new mAb/insulin capacity to drive high‑margin growth in chronic disease markets.

IQVIA Q4 FY 2026: revenue up 4.7 %, margin gains, but net profit falls 12.3 % from higher input costs and currency swings. High‑margin diagnostics drive growth while hedging stays key.